Linden Thomas Advisory Services LLC Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Linden Thomas Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,397 shares of the medical research company's stock after acquiring an additional 651 shares during the period. Linden Thomas Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $2,686,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TMO. Cypress Advisory Group LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $253,000. Intact Investment Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after purchasing an additional 660 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. Deutsche Bank AG increased its holdings in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after buying an additional 114,277 shares during the last quarter. Finally, Hancock Whitney Corp increased its holdings in Thermo Fisher Scientific by 0.6% during the fourth quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after buying an additional 30 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock traded down $6.70 during trading on Wednesday, hitting $419.47. 2,735,091 shares of the company's stock traded hands, compared to its average volume of 1,985,486. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The business has a fifty day simple moving average of $409.11 and a 200 day simple moving average of $478.29. The stock has a market capitalization of $158.35 billion, a price-to-earnings ratio of 24.60, a P/E/G ratio of 2.23 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.11 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Analyst Upgrades and Downgrades

A number of analysts have commented on TMO shares. Scotiabank reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. UBS Group cut shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and reduced their target price for the company from $500.00 to $460.00 in a report on Tuesday. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Argus reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Finally, The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $601.05.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.